Please login to the form below

Not currently logged in
Email:
Password:

Auspex

This page shows the latest Auspex news and features for those working in and with pharma, biotech and healthcare.

FDA approves Teva's Huntington's disease drug at second attempt

FDA approves Teva's Huntington's disease drug at second attempt

Deutetrabenazine was acquired by Teva when it bought  Auspex Pharma for $3.5bn in March 2015.

Latest news

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    Teva's drug SD 809 for the treatment of Huntington's disease was part of the acquisition of Auspex at a cost of $3.5bn.

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    21, 000. Auspex / Teva. Company acquisition. Phase 3 product for Huntington's Chorea deuterium technology platform.

  • Pharma deals in March 2015 Pharma deals in March 2015

    21.0. 43. 60%. Auspex. Teva. 3.5. No sales. 42%. Ikaria. Mallinckrodt. ... For example, this month Teva paid $3.5bn to acquire a loss-making company, Auspex Pharmaceuticals, with a pipeline of CNS products including one in phase III.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics